Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amer AminAlexandar BlazevskiJames E ThompsonMatthijs Jv ScheltemaMichael S HofmanDeclan G MurphyNathan L LawrentschukNiranjan SathianathenJada KapoorHenry H WooVenu ChalasaniKrishan RasiahPim J van LeeuwenReuben TangThomas CusickPhillip D StrickerLouise EmmettPublished in: BJU international (2020)
This trial will provide robust prospective data to determine the diagnostic ability of PSMA-PET/CT used in addition to mpMRI. It will establish if certain patients can avoid biopsy in the investigation of PCa.
Keyphrases
- pet ct
- positron emission tomography
- computed tomography
- prostate cancer
- clinical trial
- study protocol
- pet imaging
- end stage renal disease
- phase ii
- ejection fraction
- randomized controlled trial
- newly diagnosed
- radical prostatectomy
- chronic kidney disease
- magnetic resonance imaging
- phase iii
- prognostic factors
- patient reported outcomes
- open label
- ultrasound guided
- single molecule
- dual energy
- cross sectional
- patient reported
- benign prostatic hyperplasia
- high speed